Benefits
Fewer URTI sick days (90-day RCT)
Randomized double-blind placebo-controlled trial in 34 endurance-trained adults: 367 mg/day BetaVia Complete for 90 days produced 3.3 fewer sick days per person vs placebo (1.46 ± 1.01 vs 4.79 ± 1.47, p=0.041). Endurance-trained athletes are an immune-vulnerable population due to exercise-induced transient immunosuppression.
Fewer URTI symptoms and episodes
Same trial documented: fewer total URTI symptoms (12.62 vs 42.29 per person, p=0.029), fewer URTI symptom days (5.46 vs 15.43, p=0.019), and fewer URTI episodes (2.62 vs 4.79, p=0.032). All measured via the 24-item Wisconsin Upper Respiratory Symptom Survey — a validated instrument.
Lower URTI severity
Global severity measured as area under the curve for URTI symptoms was substantially lower with BetaVia (17.50 vs 89.79, p=0.0499) — indicating not just fewer events but milder illness when illness did occur. Practical real-world relevance for athletes and active populations.
Early-onset effect (30-day analysis)
Subgroup analysis showed sick days, symptoms, and global severity were significantly fewer in the BetaVia group over just the first 30 days vs placebo. Faster onset of immune support effect than some immune ingredients that require months of priming.
Algae-specific beta-glucan structure
Euglena paramylon is structurally distinct from yeast or oat beta-glucans — it's a pure linear beta-1,3-glucan without the beta-1,6 branching of yeast beta-glucans. Stored as free crystalline granules rather than cell-wall components. This structural distinctiveness may affect immune cell interaction kinetics.
Excellent safety profile
All safety outcomes (clinical chemistry, hematology, vitals, adverse events) within clinically normal ranges in the 90-day trial. Genotoxicity and subchronic toxicity studies found no evidence of toxicity up to 50,000 ppm from diet. GRAS-affirmed for food/beverage applications. Kosher, Halal, vegetarian, gluten-free, allergen-free, non-GMO.
Mechanism of action
Dectin-1 receptor activation
Beta-1,3-glucans bind to the dectin-1 pattern recognition receptor on innate immune cells (macrophages, neutrophils, dendritic cells). This binding 'primes' the innate immune system — enhancing pathogen recognition and response capacity without triggering inappropriate inflammation. The primary mechanism underlying all beta-glucan immune effects.
Innate immune cell priming
Primed innate immune cells respond faster and more effectively to subsequent pathogen encounters — a phenomenon sometimes called 'trained immunity.' Mechanism distinct from adaptive immunity (antibody-mediated) and operates without need for specific prior pathogen exposure.
Gut-immune axis (postbiotic effect)
Beta-glucans interact with gut-associated lymphoid tissue (GALT) — the largest collection of immune cells in the body. Kemin positions BetaVia as a postbiotic — supporting both immune function (via dectin-1) and gastrointestinal health (via direct gut interaction). Bidirectional gut-immune effects support broader respiratory and digestive resilience.
Crystalline paramylon delivery
Euglena stores beta-glucan as crystalline paramylon granules — a distinct physical form vs the matrix-bound beta-glucans in yeast cell walls. May affect intestinal interaction with M cells and Peyer's patches that sample the gut contents for immune surveillance.
Clinical trials
Randomized double-blind placebo-controlled trial (NCT03518281) in 34 healthy endurance-trained adults. Intervention: 367 mg/day BetaVia Complete vs placebo for 90 days.
Clinical population described in trial publication.
Randomized double-blind placebo-controlled trial (NCT03518281) in 34 healthy endurance-trained adults. Intervention: 367 mg/day BetaVia Complete vs placebo for 90 days. Outcomes (all per-person, BG vs PLA): sick days 1.46 vs 4.79 (p=0.041); URTI symptoms 12.62 vs 42.29 (p=0.029); symptom days 5.46 vs 15.43 (p=0.019); episodes 2.62 vs 4.79 (p=0.032); global severity AUC 17.50 vs 89.79 (p=0.0499). Early effects significant by 30 days. All safety markers normal. Published in.
Genotoxicity and subchronic toxicity studies of dried fermentate from the same proprietary Euglena gracilis strain found no evidence of toxicity up to 50,000 ppm from diet.
Clinical population described in trial publication.
Genotoxicity and subchronic toxicity studies of dried fermentate from the same proprietary Euglena gracilis strain found no evidence of toxicity up to 50,000 ppm from diet. No mutagenic properties, no gross toxicity, no abnormal behavior or pathology in rat studies. Supports GRAS affirmation for food and beverage applications.